Lonza and NeuroSense Partner to Develop Exosome-derived Biomarkers

Lonza and NeuroSense Therapeutics have collaborated to identify exosome-derived biomarkers to expedite the diagnosis and management of neurodegenerative disorders.  

The collaboration will center on assessing physiological alterations in patients with neurodegenerative conditions. Lonza’s specialist insights are expected to aid Neurosense with their end objective.  

NeuroSense will leverage its extensive knowledge of biomarkers in the realm of neurodegenerative conditions for the collaboration.  

Lonza will create and refine a technique for quantifying biomarkers from exosomes derived from neurons.  

Alon Ben-Noon, the head executive at Neuroscience, commented, “We believe this collaboration could be a game-changer for the ALS and neurodegeneration field, as findings in such biomarkers may advance early diagnosis and treatment as well as expedite the regulatory pathway for new treatments for the millions of people who suffer from neurodegenerative diseases.”  

Ben-Noon went on to add, “Collaborating with Lonza enables us to tap into some of the world’s top experts in exosome-based therapies research to develop another important measure of PrimeC’s efficacy.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.